InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,338.80
(
0.39%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.79
(
0.43%
)
Bitcoin
61,392.76
(
-0.35%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Bickema

Send PM Follow Ignore
Followers 20
Posts 1631
Boards Moderated 0
Alias Born 11/10/2010

Bickema

Re: DewDiligence post# 223659

Tuesday, 02/19/2019 9:27:22 AM

Tuesday, February 19, 2019 9:27:22 AM

Post# of 252412

Ocaliva (OCA) is an FXR agonist. I’ve posted on numerous occasions that I don’t think Ocaliva has what it takes to garner big sales, due to its side-effect profile, and the top-line REGENERATE data are consistent with such a viewpoint



Good news for ENTA? Can they avoid the side effects you speak of?

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up